Cargando…
Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938239/ https://www.ncbi.nlm.nih.gov/pubmed/33692688 http://dx.doi.org/10.3389/fphar.2021.603345 |
| _version_ | 1783661559472455680 |
|---|---|
| author | Thölking, Gerold Reuter, Stefan |
| author_facet | Thölking, Gerold Reuter, Stefan |
| author_sort | Thölking, Gerold |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7938239 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79382392021-03-09 Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients Thölking, Gerold Reuter, Stefan Front Pharmacol Pharmacology Frontiers Media S.A. 2021-02-23 /pmc/articles/PMC7938239/ /pubmed/33692688 http://dx.doi.org/10.3389/fphar.2021.603345 Text en Copyright © 2021 Thölking and Reuter. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Pharmacology Thölking, Gerold Reuter, Stefan Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients |
| title | Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients |
| title_full | Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients |
| title_fullStr | Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients |
| title_full_unstemmed | Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients |
| title_short | Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients |
| title_sort | commentary: the clinical impact of the c(0)/d ratio and the cyp3a5 genotype on outcome in tacrolimus treated kidney transplant recipients |
| topic | Pharmacology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938239/ https://www.ncbi.nlm.nih.gov/pubmed/33692688 http://dx.doi.org/10.3389/fphar.2021.603345 |
| work_keys_str_mv | AT tholkinggerold commentarytheclinicalimpactofthec0dratioandthecyp3a5genotypeonoutcomeintacrolimustreatedkidneytransplantrecipients AT reuterstefan commentarytheclinicalimpactofthec0dratioandthecyp3a5genotypeonoutcomeintacrolimustreatedkidneytransplantrecipients |